Journal of Business Ethics 77 (1):73 - 84 (2007)
This paper examines one nascent entrepreneurial endeavour intended by Canada's Stem Cell Network to catalyze the commercialization of stem cell research: the creation of a company called "Aggregate Therapeutics". We argue that this initiative, in its current configuration, is likely to result in a breach of public trust owing to three inter-related concerns: conflicts of interest; corporate influence on the university research agenda; and the failure to provide some form of direct return for the public's substantial tax dollar investment. These concerns are common to many efforts to commercialize academic science but are rendered particularly acute in this case given the therapeutic promise of stem cell research and the considerable number of resources related to stem cell research in Canada, which Aggregate Therapeutics is expected to pool. We do, however, believe that the company can be altered to guard against a violation of the public's trust, and so we present concrete modifications to its structure, which we contend should be given immediate consideration
|Keywords||biotechnology Canada commercialization governance intellectual property patent public trust stem cell|
|Categories||categorize this paper)|
References found in this work BETA
Changes in Academy/Industry/State Relations in Canada: The Creation and Development of the Networks of Centres of Excellence. [REVIEW]Donald Fisher, Janet Atkinson-Grosjean & Dawn House - 2001 - Minerva 39 (3):299-325.
Remember Asilomar? Reexamining Science's Ethical and Social Responsibility.Alexander Morgan Capron & Renie Schapiro - 2001 - Perspectives in Biology and Medicine 44 (2):162-169.
Commentary: What Did the Asilomar Exercise Accomplish, What Did It Leave Undone?Maxine Singer - 2001 - Perspectives in Biology and Medicine 44 (2):186-191.
Public Goods and Fair Prices: Balancing Technological Innovation with Social Well‐Being.Baruch Brody - 1996 - Hastings Center Report 26 (2):5-11.
Universities in the Marketplace: The Commercialization of Higher Education.Derek Bok - 2004 - British Journal of Educational Studies 52 (1):85-86.
Citations of this work BETA
Policy Design for Human Embryo Research in Canada: An Analysis (Part 2 of 2). [REVIEW]Françoise Baylis & Matthew Herder - 2009 - Journal of Bioethical Inquiry 6 (3):351-365.
Similar books and articles
The Ethics and Politics of Small Sacrifices in Stem Cell Research.Glenn McGee & Arthur L. Caplan - 1999 - Kennedy Institute of Ethics Journal 9 (2):151-158.
Social Experiments in Stem Cell Biology.Melinda B. Fagan - 2011 - Perspectives on Science 19 (3):235-262.
Will Embryonic Stem Cells Change Health Policy?William M. Sage - 2010 - Journal of Law, Medicine & Ethics 38 (2):342-351.
Stem Cell Research and Economic Promises.Timothy Caulfield - 2010 - Journal of Law, Medicine & Ethics 38 (2):303-313.
Translating Stem Cell Research: Challenges at the Research Frontier.David Magnus - 2010 - Journal of Law, Medicine & Ethics 38 (2):267-276.
Uncertain Translation, Uncertain Benefit and Uncertain Risk: Ethical Challenges Facing First-in-Human Trials of Induced Pluripotent Stem (Ips) Cells.Ronald K. F. Fung & Ian H. Kerridge - 2013 - Bioethics 27 (2):89-96.
Moral Complicity in Induced Pluripotent Stem Cell Research.Mark T. Brown - 2009 - Kennedy Institute of Ethics Journal 19 (1):pp. 1-22.
Stem Cell Research: An Ethical Evaluation of Policy Options.Nikolaus Knoepffler - 2004 - Kennedy Institute of Ethics Journal 14 (1):55-74.
Added to index2009-01-28
Total downloads15 ( #302,590 of 2,143,766 )
Recent downloads (6 months)1 ( #386,855 of 2,143,766 )
How can I increase my downloads?
There are no threads in this forum
Nothing in this forum yet.